<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736358</url>
  </required_header>
  <id_info>
    <org_study_id>12-02-244</org_study_id>
    <nct_id>NCT01736358</nct_id>
  </id_info>
  <brief_title>The Use of Intranasal Ketoralac for Pain Management (Sprix)</brief_title>
  <official_title>Evaluating Post-operative Pain Management Efficacy of Intra Nasal Ketorolac in Ambulatory Urological Surgeries-A Randomized Double-blinded Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite an overall reduction in the perioperative complication rate, post operative pain
      management after ureteroscopic removal of stones (URS) remains a major factor delaying
      discharge of patients. The investigators hypothesize that perioperative usage of intranasal
      ketorolac will provide a reduction in post operative opioid requirements, better post
      operative pain control, higher anesthesia satisfaction and faster recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence and incidence of urolithiasis, or kidney stone disease, are increasing in the
      general population. Life-time incidence of urolithiasis is estimated to be between 5%- 12%.
      The treatment of kidney stones depends on stone type and size, symptom severity, and the
      presence of obstruction.

      URS is a common ambulatory procedure as improved technological advances and increased
      clinical utilization have helped decrease postoperative complications. Despite an overall
      reduction in the perioperative complication rate, post operative pain management after URS
      remains a major factor delaying discharge of patients.

      Post operative pain after URS is usually treated with opioids and non steroidal anti
      inflammatory drugs. Intranasal ketorolac (SprixTM) is an FDA approved pain formulation for
      short term management (5 days) of moderate to moderately severe pain that requires analgesia
      at the opioid level. The efficacy of intranasal ketorolac formulation was demonstrated in
      placebo-controlled studies in patients following major surgeries.

      The primary objective of the study is to evaluate the role perioperative usage of single-dose
      of intranasal ketorolac on immediate post operative opioid requirements. Secondary objectives
      of the study are to (a) evaluate the post operative pain score 30 minutes after surgery, 1
      hour after surgery, and 2 hours after surgery, (b) find the incidence of immediate (until
      discharge) and 24hrs post operative side effects in the target population, (c) find the level
      of anesthesia satisfaction in the target population, (d) find the time to discharge in the
      target population, (e) compare the two groups post anesthesia discharge score.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis showed futility of primary endpoint
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Opioid Requirements</measure>
    <time_frame>3 hours after surgery</time_frame>
    <description>this study will assess the effect of perioperative usage of single-dose of intranasal ketorolac on post operative opioid requirements within 3 hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Operative Pain Score</measure>
    <time_frame>30 minutes after surgery</time_frame>
    <description>To evaluate the post operative pain score using the Visual Analog Scale (VAS) 30 minutes after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Pain Score</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>To evaluate the post operative pain score using the Visual Analog Scale (VAS) 1 hour after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Pain Scale</measure>
    <time_frame>2 hours after surgery</time_frame>
    <description>To evaluate the post operative pain score using the Visual Analog Scale (VAS) 2 hours after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Postoperative Side Effects</measure>
    <time_frame>24 hours after procedure</time_frame>
    <description>To find the incidence of immediate (until discharge) and 24hrs post operative side effects in the target population.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Postoperative Pain Management</condition>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>Intranasal Ketoralac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Ketoralac</intervention_name>
    <description>15.75 mg of Sprix in each nostril 20 minutes before end of surgery</description>
    <arm_group_label>Intranasal Ketoralac</arm_group_label>
    <other_name>Sprix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ureteroscopic stone removal surgeries with stenting

          -  Age â‰¥ 18 years and &lt; 65 years

          -  Stable patient with stable vital signs

          -  Mentally competent and is able to understand consent form

        Exclusion Criteria:

          -  Unstable patients

          -  Patients with multiple trauma sites

          -  Patients with allergies to ketorolac or any of the components in the nasal spray
             preparation

          -  Patients with active peptic ulcer disease

          -  History of asthma, urticaria, or other allergic-type reactions after taking aspirin or
             other NSAIDs

          -  Renal disease or at risk for renal failure due to volume depletion

          -  Pregnant or nursing mothers

          -  Nasal abnormality or illness that could affect the absorption of intranasal medication
             (such as: nasal discharge, rhinitis, acute upper respiratory infection, acute
             epistaxis, nasal polyp, nasal tumor)

          -  Any other contraindication to the use of Sprix, or in whom use of Sprix would not be
             consistent with the approved package insert
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Singh Nair, MD</last_name>
    <role>Study Director</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center- Weiler Division</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saigal CS, Joyce G, Timilsina AR; Urologic Diseases in America Project. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int. 2005 Oct;68(4):1808-14.</citation>
    <PMID>16164658</PMID>
  </reference>
  <reference>
    <citation>Pak CY, Resnick MI, Preminger GM. Ethnic and geographic diversity of stone disease. Urology. 1997 Oct;50(4):504-7.</citation>
    <PMID>9338722</PMID>
  </reference>
  <reference>
    <citation>Peschel R, Janetschek G, Bartsch G. Extracorporeal shock wave lithotripsy versus ureteroscopy for distal ureteral calculi: a prospective randomized study. J Urol. 1999 Dec;162(6):1909-12.</citation>
    <PMID>10569535</PMID>
  </reference>
  <reference>
    <citation>Tiselius HG. Epidemiology and medical management of stone disease. BJU Int. 2003 May;91(8):758-67. Review.</citation>
    <PMID>12709088</PMID>
  </reference>
  <reference>
    <citation>Erhard M, Salwen J, Bagley DH. Ureteroscopic removal of mid and proximal ureteral calculi. J Urol. 1996 Jan;155(1):38-42. Erratum in: J Urol 1996 Mar;155(3):1039.</citation>
    <PMID>7490892</PMID>
  </reference>
  <reference>
    <citation>Cheung MC, Lee F, Leung YL, Wong BB, Chu SM, Tam PC. Outpatient ureteroscopy: predictive factors for postoperative events. Urology. 2001 Dec;58(6):914-8.</citation>
    <PMID>11744457</PMID>
  </reference>
  <reference>
    <citation>Bromwich EJ, Lockyer R, Keoghane SR. Day-case rigid and flexible ureteroscopy. Ann R Coll Surg Engl. 2007 Jul;89(5):526-8.</citation>
    <PMID>17688729</PMID>
  </reference>
  <reference>
    <citation>Ahn ST, Kim JH, Park JY, Moon du G, Bae JH. Acute postoperative pain after ureteroscopic removal of stone: incidence and risk factors. Korean J Urol. 2012 Jan;53(1):34-9. doi: 10.4111/kju.2012.53.1.34. Epub 2012 Jan 25.</citation>
    <PMID>22323972</PMID>
  </reference>
  <reference>
    <citation>Moodie JE, Brown CR, Bisley EJ, Weber HU, Bynum L. The safety and analgesic efficacy of intranasal ketorolac in patients with postoperative pain. Anesth Analg. 2008 Dec;107(6):2025-31. doi: 10.1213/ane.0b013e318188b736. Erratum in: Anesth Analg. 2009 Mar;108(3):991. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.</citation>
    <PMID>19020154</PMID>
  </reference>
  <reference>
    <citation>McAleer SD, Majid O, Venables E, Polack T, Sheikh MS. Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. J Clin Pharmacol. 2007 Jan;47(1):13-8.</citation>
    <PMID>17192497</PMID>
  </reference>
  <reference>
    <citation>Brown C, Moodie J, Bisley E, Bynum L. Intranasal ketorolac for postoperative pain: a phase 3, double-blind, randomized study. Pain Med. 2009 Sep;10(6):1106-14. doi: 10.1111/j.1526-4637.2009.00647.x. Epub 2009 Jul 6. Erratum in: Pain Med. 2011 Jun;12(6):990. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.</citation>
    <PMID>19594851</PMID>
  </reference>
  <reference>
    <citation>Singla N, Singla S, Minkowitz HS, Moodie J, Brown C. Intranasal ketorolac for acute postoperative pain. Curr Med Res Opin. 2010 Aug;26(8):1915-23. doi: 10.1185/03007995.2010.495564. Erratum in: Curr Med Res Opin. 2012 Jun;28(6):1052.</citation>
    <PMID>20557145</PMID>
  </reference>
  <reference>
    <citation>Grant GM, Mehlisch DR. Intranasal ketorolac for pain secondary to third molar impaction surgery: a randomized, double-blind, placebo-controlled trial. J Oral Maxillofac Surg. 2010 May;68(5):1025-31. doi: 10.1016/j.joms.2009.10.023. Epub 2010 Mar 5.</citation>
    <PMID>20207062</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <results_first_submitted>August 8, 2019</results_first_submitted>
  <results_first_submitted_qc>February 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2020</results_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Singh Nair</investigator_full_name>
    <investigator_title>Associate Professor, Dept of Urology</investigator_title>
  </responsible_party>
  <keyword>Sprix</keyword>
  <keyword>Intranasal ketoralac</keyword>
  <keyword>Ketoralac</keyword>
  <keyword>Urolithiasis</keyword>
  <keyword>Kidney stone</keyword>
  <keyword>Uretal stone</keyword>
  <keyword>Ureteroscopic removal of stones</keyword>
  <keyword>URS</keyword>
  <keyword>Pain management</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intranasal Ketoralac</title>
          <description>A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
Intranasal Ketoralac: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
Placebo: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Ketoralac</title>
          <description>A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
Intranasal Ketoralac: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
Placebo: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="12.4"/>
                    <measurement group_id="B2" value="49" spread="9.3"/>
                    <measurement group_id="B3" value="48" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Opioid Requirements</title>
        <description>this study will assess the effect of perioperative usage of single-dose of intranasal ketorolac on post operative opioid requirements within 3 hours after surgery.</description>
        <time_frame>3 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Ketoralac</title>
            <description>A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
Intranasal Ketoralac: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
Placebo: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Opioid Requirements</title>
          <description>this study will assess the effect of perioperative usage of single-dose of intranasal ketorolac on post operative opioid requirements within 3 hours after surgery.</description>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.43" lower_limit="23.87" upper_limit="51.30"/>
                    <measurement group_id="O2" value="30" lower_limit="22.05" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Pain Score</title>
        <description>To evaluate the post operative pain score using the Visual Analog Scale (VAS) 30 minutes after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain.</description>
        <time_frame>30 minutes after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Ketoralac</title>
            <description>A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
Intranasal Ketoralac: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
Placebo: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Pain Score</title>
          <description>To evaluate the post operative pain score using the Visual Analog Scale (VAS) 30 minutes after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="3.5" lower_limit="0" upper_limit="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Pain Score</title>
        <description>To evaluate the post operative pain score using the Visual Analog Scale (VAS) 1 hour after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain.</description>
        <time_frame>1 hour after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Ketoralac</title>
            <description>A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
Intranasal Ketoralac: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
Placebo: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Pain Score</title>
          <description>To evaluate the post operative pain score using the Visual Analog Scale (VAS) 1 hour after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0" upper_limit="5.7"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Pain Scale</title>
        <description>To evaluate the post operative pain score using the Visual Analog Scale (VAS) 2 hours after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain.</description>
        <time_frame>2 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Ketoralac</title>
            <description>A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
Intranasal Ketoralac: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
Placebo: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Pain Scale</title>
          <description>To evaluate the post operative pain score using the Visual Analog Scale (VAS) 2 hours after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="7.7"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Postoperative Side Effects</title>
        <description>To find the incidence of immediate (until discharge) and 24hrs post operative side effects in the target population.</description>
        <time_frame>24 hours after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Ketoralac</title>
            <description>A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
Intranasal Ketoralac: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
Placebo: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Postoperative Side Effects</title>
          <description>To find the incidence of immediate (until discharge) and 24hrs post operative side effects in the target population.</description>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Ketoralac</title>
          <description>A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
Intranasal Ketoralac: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
Placebo: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.David Hoenig</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <email>dhoenig@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

